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Abstract
Healthcare providers continue to seek improved methods for preventing, detecting and treating diseases that affect human survival and
quality of life. At the same time, there will always be ﬁnancial constraints because of limited societal resources. Many of the discussions
on how to provide economically sound solutions to this challenge have not fully engaged the input of clinicians in the ﬁeld. The purpose
of this review is to increase economic knowledge for clinicians. We cover healthcare cost elements and methods used to assign value
to a health outcome. We outline the challenges in conducting economic studies in the ﬁeld of infectious diseases. Finally, we discuss the
meaning of efﬁciency from multiple perspectives, and how the concept of economic externalities applies to infectious diseases.
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Introduction
The purpose of economic knowledge for clinicians is to
enable them to better understand the forces affecting their
workplace, to accurately interpret economic results, and to
develop meaningful future research. Cost is an element of
any decision [1,2]. Clinicians who understand economics may
contribute more effectively to patient, workplace and
national decision-making processes. A decision in healthcare
may involve choosing between alternative treatment strate-
gies by evaluating cost, quality, and how much is available to
spend. Implementing or expanding a service is also an eco-
nomic decision. Examples in healthcare include aggressive
human immunodeﬁciency virus (HIV) screening, enhanced
tuberculosis detection, methicillin-resistant Staphylococcus
aureus search and destroy methods, improved infection con-
trol, and promotion of judicious antimicrobial use [3–11].
We will review healthcare costs and beneﬁts, and how they
are measured, and use examples from infectious diseases.
The major players in healthcare economics are providers
supplying healthcare services, patients receiving the beneﬁts
of healthcare, and often third parties, who pay all or most of
the bill for services provided [12,13].
Healthcare Costs
On one side of a healthcare transaction is the provider—this
may be a clinician, clinic, pharmacy, imaging centre, hospital,
or healthcare system. Deﬁning provider cost is difﬁcult in
healthcare, because a multitude of goods are produced by a
bevy of personnel [14]. They are consumed in seemingly inﬁ-
nite combinations by individual patients. There are also
uncertainties in patient diagnosis, severity of illness, testing
accuracy, and treatment response, making future cost predic-
tions difﬁcult [12,15]. Cost deﬁnitions that are useful in eco-
nomics are ‘ﬁxed’, ‘variable’, and ‘marginal’ [2,12,13,16–18].
They exist for the patient, hospital and societal perspectives,
but are uniquely complex at the hospital level [17].
Hospitals incur costs for building space, equipment, and
renovations. Those costs are considered to be ﬁxed from the
hospital perspective, because they will not change, despite
output or number of patients treated [2,12,13,18]. For exam-
ple, the cost of buying and installing a computed tomography
(CT) scanner is constant, no matter how many scans are per-
formed. The more scans performed, the lower the ﬁxed
equipment cost per scan. On the other hand, variable costs
do change with output or number of patients treated
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[2,12,13,18]. Examples include doses of antibiotics, blood cul-
ture bottles, or wound dressings. The more is provided, the
higher the cost. Marginal cost is deﬁned as the change in total
cost needed to produce one additional unit of output
[12,13,19]. It is important to keep in mind that costs depend
on the time frame. Although the overall CT cost is high, one
more scan only increases the variable cost over the short
term. Therefore, marginal costs initially decrease, owing to
economies of scale [12,18]. In the CT example, the machine
is already paid for, the labour costs per scan are lower, owing
to reduced staff idle time, and high-volume purchases of con-
trast media will lower variable costs. Marginal cost will later
rise with continued increases in volume as the facility
becomes overwhelmed and inefﬁcient [14]. Semi-ﬁxed costs
(also known as step-ﬁxed costs) are non-proportional incre-
mental cost jumps [12]. For example, the ﬁxed cost per CT
scan initially drops as the number of scans goes up, until a
new scanner and additional technicians are needed to meet
demand. Semi-variable costs (also known as mixed costs)
have both ﬁxed and variable elements [12]. Examples include
utilities and service contracts, which are similar to mobile
phone contracts. There is a reliable base or ﬁxed cost unless
the number of minutes is exceeded, and then each additional
minute costs more. Sunk costs are those that are unaffected
by a current decision, or are gone forever [18].
The authors and colleagues have conducted a number of
economic studies from the provider economic perspective
[13,20–23]. Important study tasks are to identify patient
resources used, and then to determine the total cost for
each of those resources. For hospital stays, there is the total
length of stay, the location of treatment in intensive–care or
regular wards, and what tests, treatments and procedures
the patient received [20]. One can simply multiply the length
of stay by the average cost per day [21]. However, for many
cost comparisons, the difference between subgroups will
require direct measurement of healthcare resource elements
that differ signiﬁcantly between individual patients. This
requires a method for allocating the entire hospital or clinic
cost to speciﬁc measurable patient services. For example, a
CT scan requires an imaging area, the scanner, a technician,
a radiologist, and contrast material. Those costs are speciﬁc
to CT scans, and are designated as ‘service’ costs [13]. Ser-
vice costs are directly measureable for individual patients
who receive a CT scan. However, there are also costs for
the payroll department in managing employee paychecks, and
the environmental department in keeping the entire hospital
clean, and electrical power expenses to keep the imaging
rooms heated and lit, and the scanner operating. These are
called ‘support’ costs, as opposed to service costs [13].
Support costs such as electricity and environmental workers
are allocated to each department by the proportion of
square footage occupied [13]. Support costs such as worker
beneﬁts or payroll departments are allocated by proportion
of full-time equivalent employees working [13]. This becomes
more complex for large organizations where the environ-
mental department cleans the CT scanner area, the patient-
care rooms, the radiologist reading room, and the payroll
department ofﬁces. The payroll department manages salaries
for CT technicians, nurses, and environmental workers.
Errors in allocation can occur unless the interactions
between non-patient-care departments, such as environmental
and payroll, are accounted for. The multiple-distribution
TABLE 1. Healthcare cost elements and examples
One-time costs
Hospital building—allocated once directly per year
Costs amortized over life of building, resulting in an annual ﬁxed cost
Cost is allocated by square footage occupied by each department
Rent may be a substitute
Capital and equipment—allocated once directly per year; may need replacement
or repair
Costs amortized over expected life of equipment
Used in speciﬁc departmental areas
Service examples—computed tomography scanners, ventilators
Support examples—administrative ofﬁce equipment
Annual support costs
Non-salary support—allocated once directly per year
Used throughout the facility
Examples
Cleaning supplies allocated by square footage
Employee beneﬁts allocated by full-time equivalent employees
Salary support—labour costs allocated using multiple distribution
Function throughout the facility
Examples
Environmental allocated by square footage
Payroll allocated by full-time employee equivalents
See Fig. 1 for illustration of allocation of support costs to service centre
departments
Service centre costs—labour
Providers: directly provide patient care in hospitals or clinics—physicians, nurses
Tests and treatments—often occupy designated space and use specialized
equipment
Pharmacy—pharmacists
Laboratory—technicians, pathologists
Radiology—technicians, radiologists
Procedures: endoscopy, bronchoscopy—specialists
Operating room staff—anaesthesiology, surgeons
Ancillary—work directly in providing patient services to augment or facilitate
services
Clinical administration
Clerical staff
Social services
Language interpreter services
Health education
Dietary—provide patient food, dietary consultation, and sometimes staff meals
Indirect patient services—usually added to measured provider visits or ancillary
costs
Additional patient costs for an encounter, hospital day, test or treatment
Examples
Medical records
Billing and ﬁnance
Hospital information services
Materiel management (procurement, storage and delivery of supplies)
Security
Biohazardous waste disposal
Communications—pagers, phones, maintain contact numbers
Variable service centre costs—consumable supplies
Directly consumed during the provision of healthcare services
Medical supplies—central lines, wound dressings, facemasks
Laboratory supplies—culture bottles, laboratory reagents
Radiological supplies—contrast media
Pharmacy supplies—medicines, vaccines, medication bottles and caps
Miscellaneous—paper, food, patient ID bracelets
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method with reiterative equations has been used by the
authors [12,13,20–23]. The support department costs are allo-
cated to all service and support departments on the basis of
square footage or full-time equivalent employees per depart-
ment. This results in a proportion of the support cost alloca-
tion going back to support departments. This is re-allocated
again to all departments, with increasingly more support costs
being sequentially added to the patient service departments. In
the ﬁnal step, the total support cost is allocated to service
centres only. The ﬁnal result is that all hospital operating costs
are allocated to patient service centres on the basis of esti-
mated use. The cost elements and steps of this allocation pro-
cess are shown in Table 1 and Fig. 1. All of these costs are
considered to be healthcare or hospital perspective costs.
Healthcare efﬁciency is an important concept. ‘Technical
efﬁciency’ deﬁnes how efﬁciently patients and healthcare out-
puts are produced by a facility with its available resources
[13,24]. This may require internal re-allocation of resources
when conditions change. For example, during the recent
H1N1 inﬂuenza outbreak, our hospital re-allocated the Obser-
vation Unit space and staff to care for H1N1 patients, and
anticipated delaying elective surgery to divert respiratory ther-
apists and recovery room nurses to inﬂuenza care. In contrast,
the goal of ‘economic efﬁciency’ for the same healthcare facility
is to maximize third-party reimbursements relative to hospital
expenditures for healthcare services provided [13,24] (Fig. 2).
Healthcare Beneﬁts or Value
Costs for healthcare ideally lead to beneﬁts or gains in value
for patients and society. Healthcare outcomes are difﬁcult to
measure. Outcomes may simply be counted: total number of
patients treated, lives saved, or years of life saved. We often
use surrogate outcomes, such as CD4 counts in AIDS, that
have been correlated with health improvements and
expected years of life [25,26]. Utility is a concept that can be
applied to healthcare outcome measurement [26,27]. Health-
care utility combines quantity of life in years with a health-
related value or quality for each year [16,28]. The patient or
societal goal is to maximize total utility over time. Individual
utility involves consuming a sought-after good in an ideal
quantity. For example, how many litres of expired plain
vanilla ice cream would you trade for one of your favourite
ﬂavour of fresh gelato? The utility of fresh gelato can be
measured in how much money you would pay, or in how
many litres of plain vanilla ice cream you would trade [29].
Marginal utility is the additional beneﬁt gained from consum-
ing one more quantity of value. The concept of diminishing
marginal utility suggests that the ﬁrst delicious bite of your
favourite gelato has more utility than that last bite after eat-
ing an entire litre. These concepts are simple when rating
the utility of food, but become complex for health status.
In healthcare, we seek to maximize the total number of
lives saved, the years of life, and the quality of those years.
Many cost-effectiveness and cost–utility studies examine the
cost per quality-adjusted life-years (QALYs) saved [26,30,31].
Quality of life refers to general wellbeing. The QALY is on a
scale from 1.0, which is perfect health, to 0.0, which is death
[29,32]. By using QALYS, one can evaluate alternative health-
care outcomes without requiring any loss of life or years of
life [26,32]. All of these ideas have been useful in the study
of HIV testing and management. Cost studies have reported
the improvements in QALYs gained by treatment of HIV
1.  Directly allocated non-salary costs
Building costs - SF
Benefits - Fte 2.  Multiple distribution allocation of support department costs
SF SF
3.  Step-down last of support costs
SFFte Fte Fte
All support costs are eventually  
*Support costs are progressively smaller
Allocated to service departments
Patient care service departments
Patient care = Sum of service department salaries, equipment, and supplies
plus allocated: building and benefit costs
and support dept square footage and administrative cost
*Patient care costs are progressively larger
FIG. 1. Multiple-distribution allocation
of support cost to service departments
to calculate full cost of patient care.
Fte, full-time equivalent employee; SF,
square-footage.
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complications [33,34]. In fact, it has been estimated that
highly active antiretroviral therapy (HAART) has resulted in
gains of more than 3 million human years of life [35]. More
recently, initiating HAART earlier in the course of illness has
been recommended [36]. Although the medication will cost
more in the short term, this cost is balanced by the beneﬁts
of improved health and reduced infectivity. In addition, many
have moved from extensive counselling prior to HIV testing
to ‘opt-out’ programmes where HIV testing is routine [37].
The economic beneﬁts of aggressive HIV testing programmes
result from early diagnosis and treatment plus reduced HIV
transmission [3,37]. This information can be used to estimate
the future medical cost savings from prevented HIV infection.
Simple observation is another economic study method. For
example, the authors and other researchers have reported
the cost for treatment of patients with HIV/AIDS for 1 year
[20]. These data can be used to estimate savings from pre-
vented HIV infection and early HAART. We found that
patients who received comprehensive ambulatory care and
maintained high CD4 counts had fewer hospitalizations and
lower total annual costs.
Measuring QALYs requires assessing the value of a health
state as compared with a better or worse state, and how
long that difference continues [26,29,38]. A current health
state can be compared to better or worse health states. For
example, if an average healthy year has a utility of 0.92, but
an untreated spinal epidural abscess causes hemiparalysis,
which has a utility of 0.44, then a healthy patient with
new hemiparalysis has lost (0.92–0.44) or 0.48 units per year
[31,39]. If this disease had been prevented with early
diagnosis and treatment, the patient would have gained
4.8 QALYS over 10 years by avoiding hemiparalysis.
Economic evaluations of health programmes can be
expressed as money spent per QALY gained [26,31,32,38].
QALYs are used to aid society in evaluating resource alloca-
tion for diverse outcomes that affect different populations,
such as weighing the beneﬁts of improved childhood vaccina-
tion rates as compared with deciding what CD4 count
warrants starting antiretroviral therapy in HIV patients
[32,36].
There are three widely used methods of measuring where
different health states rank on this scale: the visual analogue
scale, time trade-off, and standard gamble [16,26,29,32,40].
Each method seeks to measure and compare patient or soci-
etal preferences for different health states [32,40]. For the
visual analogue scale, respondents rate a state of health on a
simple linear scale. In time trade-off, respondents choose
between remaining in a state of bad health or achieving an
improved or perfect state of health, but having a shorter life-
span. In a standard gamble, respondents select one of two
choices: remain in a current state of bad health, or undergo
a medical intervention with a particular probability of cure
and another probability of death. Alternatively, patients can
decide what chance of health deterioration they would risk
to extend their lifespan. The goal of all these methods is to
compare different healthcare strategies and outcomes for a
single disorder and across multiple disorders [32].
There are ongoing efforts to better understand and mea-
sure health preferences [26,41–43]. When these healthcare
assessments are being made, uncertainty and risk must be
taken into account [29,42–44]. The risk of treatment and the
promise of improved or extended life-expectancy are only
probabilities. This often makes it difﬁcult for respondents
to accurately complete surveys. Controversy exists on the
Patient benefits
Reduced exposure to 
communicable diseases
Lives saved and years lived
Improved quality of life
QALYS gained
Healthcare system
Disease detection
Clinic visits
Medications
Hospital days
Procedures
Society
Food and shelter
Education
Clean energy
Traffic safety
Healthcare
Technical efficiency
Patient benefits per 
healthcare resource deployed
Economic efficiency
Reimbursements from society for healthcare services 
provided relative to healthcare system expenses
Allocative efficiency = 
= 
= 
Societal effectiveness in balancing 
priorities to maximize citizen utility 
FIG. 2. Efﬁciency—allocative, technical,
and economic. QALY, quality-adjusted
life-year.
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relative meaning and validity of different health-related
quality-of-life survey tools in different settings. One major
question is whether the utility scale from 0.0 to 1.0 is linear
or equal along its entire span. For example, is it correct to
assume that improved health from 0.2 to 0.4 has the same
value as that from 0.6 to 0.8? [29] There are also individual
disposition effects [41,43]. Some optimistic individuals will
continue to rate their current health as high quality, even as
they grow older and more frail, whereas young patients with
depression rate their quality of life as very low. Health pref-
erence results, even in the same domain, can vary with
which individuals are questioned and where they are on the
scale [44]. Imagine a scale for ambulation or getting from
place to place. At one end is a completely dependent bedrid-
den person, and at the other is a fully ambulatory athlete.
Bedridden individuals may greatly value being in a wheelchair
relative to their current state, whereas athletes may believe
that money would be wisely spent in keeping ambulatory
people out of wheelchairs, and may imagine being bedridden
as worse than death. In other words, quality of life may look
better on the way up the scale than on the way down. This
phenomenon has even been described for individual patients
[43]. Patients with colostomies rate their current health
state higher than unaffected patients would rate having an
imagined colostomy. However, after treatment, post-colos-
tomy patients also rate the past health status of colostomy
lower than those with current colostomies.
From the perspective of society, the goal is to maximize
total social utility. When resources are limited, it is difﬁcult
to determine which perspective to use in comparing health
programmes—the afﬂicted or non-afﬂicted? [32,41] Potential
health beneﬁts must also be compared with other social
goods that may be sacriﬁced, such as abundant clean energy,
effective education, and trafﬁc safety. This is the deﬁnition of
opportunity cost for society [32]. An opportunity cost rep-
resents an alternative good that must be given up, and that
would have been the next best use of a resource [16,45].
This leads to the concept of ‘allocative efﬁciency’ [42,46].
Allocative efﬁciency represents the effectiveness of a society
in allocating resources to maximize the utility for an entire
community over all of its activities and goals (Fig. 2).
Challenges in Study Design and Economic
Analysis
Infection prevention programmes are difﬁcult to assess eco-
nomically. Healthcare-acquired infection (HAI) is an impor-
tant example. The economic question is whether the
investment in HAI prevention will be rewarded with future
savings, when infection has been averted [47]. The cost anal-
ysis attempts to determine what patients would have cost
had they not developed an infection. The ﬁrst problem in
measuring the cost for infection is confounding. The manage-
ment of more severely ill patients usually requires more test-
ing and treatment procedures, more frequent encounters
with healthcare personnel, and prolonged length of stay. The
research goal is to determine how much of the expense of
hospitalization was attributable to the initial severity of illness
and how much was attributable to subsequent development
of HAI. The same is true for antimicrobial-resistant infections
(ARIs), which are often hospital-acquired or associated with
past healthcare encounters and treatments [5,21].
Several methods have been developed to answer this ques-
tion. Matched case–control methods compare the cost for
patients with a speciﬁc infection with that of controls who
are similar in every other respect, except that they did not
develop infection. This usually requires limiting the study to
patients who have infection and can be matched to satisfac-
tory controls. For example, in our recent ARI study, only
138 (73%) of a total 188 identiﬁed ARI patients could be
matched to a suitable control by propensity score. Another
strategy is to include all patients, but to use statistical meth-
ods, such as ordinary least-squares (OLS) linear regression
models, to adjust for patient factors that increase cost
[21,48]. Linear regression measures the effect of each cost
predictor used in the economic model. It is therefore impor-
tant to measure other important cost predictors, such as
patient severity of illness, comorbidities, and treatment, in
high-cost settings such as the intensive-care unit (ICU).
Regression parameter estimates represent the cost associ-
ated with each predictor, including HAI or ARI. The beneﬁt
is that an entire facility might be able to assess its total attrib-
utable cost for infection by including all patient subgroups in
the analysis. For example, the authors and colleagues used a
random sample strategy to estimate the hospital cost for HAI
over 1 year [21,22]. Our rationale was that infection control
is most effective if it is widely adopted, because patients often
transfer between treatment areas such as ICUs or operating
rooms to regular wards or recovery rooms.
The potential problem with OLS linear regression analysis
is that the method may not be perfectly applicable to health-
care cost data [49–51]. The most familiar distribution in
descriptive statistics is the normal bell-shaped curve. In con-
trast, healthcare cost data tend to be greatly skewed to the
right, with just a few patients incurring costs that are much
higher than those for the majority [49–51]. If just a few extra
HAI or ARI cases are very costly, this could bias the results.
One solution is to exclude the very high-cost outliers. The
problem is that high-cost outliers do contribute signiﬁcantly
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to healthcare cost, and it is probable that patients with HAI
and ARI are preventable outliers. There are a number of
strategies for addressing the problem of skewed data. Wins-
orizing can decrease the effect of outliers in skewed datasets
while still maintaining them in the analysis [52]. After the
dataset is arranged from least to most expensive, the individ-
ual cost for each of the extreme outliers can be replaced with
the cost of the next patient in the sequence. Analysis can
then be conducted on the Winsorized dataset. In describing
skewed data, the median is often substituted for the mean as
a more accurate representation of the data. In similar fashion,
there are statistical methods for dampening the effects of
outliers, such as median quantile regression [53]. Another
method with which to reduce the effect of outliers is to con-
vert the raw total cost numbers to a logarithm [49–51]. A
simple example is using base 10 log, where: 0 = 0; 10 = 1;
100 = 2; 1000 = 3; and so on. This procedure reduces the
relative contributions of very high numbers in a dataset that
is highly skewed to the right. Generalized linear models use
the same concept, and the results can be retransformed back
to cost units [54]. Finally, costs can be calculated by multiply-
ing the cost per day by the attributable excess length of stay.
However, the longer a patient is in the hospital, the higher
the chance of acquiring an infection. This is called endogeneity
bias, where linear regression may overestimate the length of
stay attributable to infection alone. One method of address-
ing endogeneity bias is to use a multistate proportional haz-
ard model, which controls for pre-infection length of stay
[55]. Our group recently reported cost outcomes for ARI,
including comparisons of different analytical methods [21].
For ARI, total hospital costs ranged from $25 641 to $29 069
per patient, depending on the study design and analytical
method used. The lowest cost estimate was obtained with
OLS linear regression, with adjustments made for surgery,
ICU care, comorbidities, and acute severity of illness on
admission to the hospital. The highest cost estimate was
obtained with a matched case–control design. On further
adjustment for concurrent HAI, the cost range was $18 585
to $21 208. Greater cost differences were seen when the
same economic analysis was used in different patient settings.
The attributable cost for ARI in non-ICU patients was $7200,
as compared with $47 727 in ICU patients.
The last important concept in healthcare economics is
‘externalities’ [18,27,45]. The usual economic discussion is
focused on the consumer’s payment for a good and the sell-
er’s proﬁt from selling that good. Externalities are the
unmeasured effects on third parties who were not at all
involved in the primary economic transaction between buyer
and seller. A typical example of a societal negative externality
is poor air quality caused by pollution from a factory. A
positive externality would be the beneﬁt that members of a
large apartment complex receive because one of their neigh-
bours has bought and installed very sensitive smoke and car-
bon monoxide detectors. In the event of a ﬁre, the entire
building may beneﬁt from the early alarm. These ideas are
also applicable to healthcare, especially infectious diseases. A
positive externality in healthcare might result from aggressive
HIV and tuberculosis diagnostic testing programmes [11,37].
Ten years from now, citizens may stroll past a hospital and
not know that they would have had HIV infections if the hos-
pital had not instituted aggressive HIV testing and treatment
programmes 10 years earlier. A negative externality would
be the practice of aggressive treatment of mild or suspected
infections with broad-spectrum antibiotics [9,28]. The treated
patients receive only minimal beneﬁt. Ten years from now, a
patient may die of infection caused by an antimicrobial-resis-
tant organism. In fact, recent reports have documented that
many who died during the recent H1N1 pandemic had post-
inﬂuenza pneumonia caused by methicillin-resistant S. aureus
[56]. The management of infectious diseases may represent a
unique example of positive and negative externalities occur-
ring within a single medical practice domain. The decisions
made by clinicians today may have effects that will be difﬁcult
to quantify economically in the future.
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